Creatinine‐to‐bodyweight ratio is a predictor of incident non‐alcoholic fatty liver disease: A population‐based longitudinal study
Aim Serum creatinine (Cre) is used as a surrogate marker of muscle mass. We investigated the impact of the Cre‐to‐bodyweight (BW) ratio (Cre/BW) on incident non‐alcoholic fatty liver disease (NAFLD). Methods Fatty liver disease was diagnosed by abdominal ultrasonography. In this historical cohort st...
Saved in:
| Published in: | Hepatology research Vol. 50; no. 1; pp. 57 - 66 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Wiley Subscription Services, Inc
01-01-2020
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim
Serum creatinine (Cre) is used as a surrogate marker of muscle mass. We investigated the impact of the Cre‐to‐bodyweight (BW) ratio (Cre/BW) on incident non‐alcoholic fatty liver disease (NAFLD).
Methods
Fatty liver disease was diagnosed by abdominal ultrasonography. In this historical cohort study of 13 728 participants (6397 men and 7331 women), we divided the participants into two groups by sex and into quartiles according to Cre (mg/dL)/BW (kg; Q1–4). We carried out Cox proportional hazard models, adjusting for age, alanine aminotransferase, fasting plasma glucose, systolic blood pressure, alcohol consumption, smoking status, and exercise.
Results
During the 5.1‐year follow up for men and 6.0‐year follow up for women, 2497 participants (1696 men, 801 women) developed NAFLD. The 4000‐days cumulative incidence rates of FLD for men and women were 29.6% and 16.6% in Q1, 28.2% and 10.6% in Q2, 25.5% and 8.8% in Q3, and 22.7% and 7.7% in Q4, respectively. The hazard ratios of incident NAFLD in Q1 (Cre/BW [×100]: men <1.28; women <1.17) were 1.89 (95% confidence interval 1.64–2.17, P < 0.001) in men and 2.96 (2.42–3.62, P < 0.001) in women, compared with Q4 (Cre/BW [×100]: men ≥1.61; women ≥1.51).
Conclusions
A low Cre/BW is associated with an increased risk of NAFLD. Screening Cre/BW can be used to identify individuals who are at high risk of NAFLD. |
|---|---|
| Bibliography: | Financial support: The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by pharmaceutical company, the authors received no current funding for this study, and this does not alter their adherence to all the journal policies on sharing data and materials. Conflict of interest: Y. Hashimoto received grants from Asahi Kasei Corporation outside the submitted work. M. Fukui received grants from AstraZeneca, Astellas Pharma, Nippon Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Japan, Kyowa Hakko Kirin, Kissei Pharmaceutical, MSD, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Sanofi, Ono Pharmaceutical, and Takeda Pharmaceutical, outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The other authors have nothing to disclose. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 1386-6346 1872-034X |
| DOI: | 10.1111/hepr.13429 |